Editas Medicine, Inc. cotiza a 2.75 USD y tiene una capitalización bursátil de $422M. En los últimos 12 meses ha facturado $47M con un margen de flujo de caja libre del -409.3%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL choles…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.15 | $-0.26 | $-0.06 |
| Estimado | $-0.21 | $-0.28 | $-0.24 | $-0.21 |
| Sorpresa | — | +46.4% | -8.3% | +71.4% |
| Métrica | EDIT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -394.9% | -38.6% | -356.3% |
| Net Margin | -395.0% | -33.6% | -361.4% |
| FCF Margin | -409.3% | -13.9% | -395.4% |
| ROE | -586.6% | -40.4% | -546.2% |
| ROA | -85.8% | -32.0% | -53.8% |
| Current Ratio | 3.54 | 2.84 | +0.70 |
| Debt / Equity | 1.96 | 0.28 | +1.68 |